University of California San Diego
San Diego, California, 92037, United States
NCT Number: NCT06230770
Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.
This study is active but is not currently recruiting participants.
18 year–50 year
All sexes
Observational
San Diego, California, 92037, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will report their daily bleeding patterns
Time frame: Start of GATT to 30 days
mean number of days of bleeding or spotting during the 30 days after GATT initiation
University of California, San Diego
Other
The Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating Testosterone Therapy for Gender Affirmation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03890237
Adolescent Behavior, Behavior
Zone 5, Afar Region, Ethiopia
View Trial DetailsNCT03049202
Airway Obstruction, Behavior
Stockholm, Sverige, Sweden
View Trial DetailsNCT07726290
Artifical Intelligence, Behavior
Cairo, Egypt
View Trial DetailsNCT06345573
Behavior, Behavioral Symptoms
Zurich, Canton of Zurich, Switzerland
View Trial Details